Dose-related ocular adverse events ( chromatopsia , @ % emixustat vs. @ % placebo and delayed dark adaptation , @ % emixustat vs. @ % placebo ) were mild to moderate in severity , and the majority resolved on study or within @ days to @ days after study drug cessation .